JP2024539609A - コロナウイルスワクチン - Google Patents

コロナウイルスワクチン Download PDF

Info

Publication number
JP2024539609A
JP2024539609A JP2024521255A JP2024521255A JP2024539609A JP 2024539609 A JP2024539609 A JP 2024539609A JP 2024521255 A JP2024521255 A JP 2024521255A JP 2024521255 A JP2024521255 A JP 2024521255A JP 2024539609 A JP2024539609 A JP 2024539609A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
polypeptide
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539609A5 (cg-RX-API-DMAC7.html
Inventor
ジョナサン ルーク ヒーニー,
スネハ ビシュワナス,
ジョージ カーネル,
デイビッド ウェルズ,
マッテオ フェラーリ,
ベネディクト アスバッハ,
ラルフ ヴァーグナー,
マルティーナ ビルマイアー,
パトリック ネッカーマン,
Original Assignee
ディオシンバックス リミテッド
ザ チャンセラー, マスターズ アンド スカラーズ オブ ザ ユニバーシティー オブ ケンブリッジ
ウニヴェルジテート レーゲンスブルク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2114318.5A external-priority patent/GB202114318D0/en
Priority claimed from GBGB2214126.1A external-priority patent/GB202214126D0/en
Application filed by ディオシンバックス リミテッド, ザ チャンセラー, マスターズ アンド スカラーズ オブ ザ ユニバーシティー オブ ケンブリッジ, ウニヴェルジテート レーゲンスブルク filed Critical ディオシンバックス リミテッド
Publication of JP2024539609A publication Critical patent/JP2024539609A/ja
Publication of JP2024539609A5 publication Critical patent/JP2024539609A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024521255A 2021-10-06 2022-10-06 コロナウイルスワクチン Pending JP2024539609A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2114318.5 2021-10-06
GBGB2114318.5A GB202114318D0 (en) 2021-10-06 2021-10-06 Coronavirus Vaccines
GBGB2214126.1A GB202214126D0 (en) 2022-09-27 2022-09-27 Coronavirus vaccines
GB2214126.1 2022-09-27
PCT/GB2022/052537 WO2023057769A1 (en) 2021-10-06 2022-10-06 Coronavirus vaccines

Publications (2)

Publication Number Publication Date
JP2024539609A true JP2024539609A (ja) 2024-10-29
JP2024539609A5 JP2024539609A5 (cg-RX-API-DMAC7.html) 2025-10-15

Family

ID=83692901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521255A Pending JP2024539609A (ja) 2021-10-06 2022-10-06 コロナウイルスワクチン

Country Status (7)

Country Link
US (1) US20250312437A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412645A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539609A (cg-RX-API-DMAC7.html)
CN (1) CN119013040A (cg-RX-API-DMAC7.html)
AU (1) AU2022358982A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234656A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023057769A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024209218A1 (en) * 2023-04-05 2024-10-10 Diosynvax Ltd Coronavirus vaccines inducing broad immunity against variants
WO2025083402A1 (en) * 2023-10-16 2025-04-24 Diosynvax Ltd Coronavirus vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
DE202021004130U1 (de) * 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
EP4103228A1 (en) * 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
CN115244077B (zh) * 2020-03-11 2025-04-29 南特细胞公司 蛋白质治疗剂
WO2021198706A2 (en) * 2020-04-01 2021-10-07 Diosynvax Ltd Coronavirus vaccines
WO2021260065A1 (en) * 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
MX2023007574A (es) * 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20240100151A1 (en) * 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
WO2022235847A1 (en) * 2021-05-04 2022-11-10 BioNTech SE Technologies for early detection of variants of interest

Also Published As

Publication number Publication date
AU2022358982A1 (en) 2024-05-23
WO2023057769A1 (en) 2023-04-13
CA3234656A1 (en) 2023-04-13
EP4412645A1 (en) 2024-08-14
US20250312437A1 (en) 2025-10-09
CN119013040A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
JP2025184979A (ja) コロナウイルスワクチン
US11759516B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
JP7655849B2 (ja) ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
US20240374710A1 (en) Vaccine Compositions For Preventing Coronavirus Disease
JP2023513913A (ja) 麻疹ベクターを用いたcovid-19免疫原性組成物及びワクチン
Law et al. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
Kim et al. A single subcutaneous or intranasal immunization with adenovirus‐based SARS‐CoV‐2 vaccine induces robust humoral and cellular immune responses in mice
Zhou et al. Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
Yang et al. Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus
US20260130984A1 (en) Highly networked immunogen composition
CN111683959A (zh) 包含非结构蛋白的寨卡病毒嵌合多表位及其在免疫原性组合物中的用途
CN119013040A (zh) 冠状病毒疫苗
Wang et al. Development and identification of porcine monoclonal antibodies against PEDV from single B cells
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ(mva)ワクチン
JP2026508394A (ja) コロナウイルスワクチン
US20250026794A1 (en) Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
WO2016130786A2 (en) Flaviviridae proteins and virions and methods of use thereof
Poh et al. Characterization of cytotoxic T‐lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD‐integrin‐binding motif
US20130337009A1 (en) Chimeric dna vaccine compositions and methods of use
Pfranger et al. Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine
Wang et al. Pseudotyped viruses for coronaviruses
Lee et al. Coronavirus nucleocapsid-based vaccine provides partial protection against hetero-species coronavirus in murine models
CN116535517B (zh) 一种重组表达pedv s蛋白受体rbd结构域的prrsv活载体疫苗株的构建及应用
US20250009873A1 (en) Methods of preventing, treating, or reducing the severity of covid-19 in immunocompromised blood cancer patients
EP4316514A1 (en) Mva-based vectors and their use as vaccine against sars-cov-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251006